The US Food and Drug Administration (FDA) has granted accelerated approval to Astellas Pharma Inc. and Seattle Genetics Inc.'s first-in-class antibody-drug conjugate (ADC) Padcev (enfortumab vedotin-ejfv), providing a new treatment option for later-stage patients with a form of cancer that can currently be very difficult to treat.
The novel therapy, which targets the nectin-4 cell surface protein highly expressed in bladder cancer, has been cleared for the treatment of adults with locally advanced or metastatic urothelial cancer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?